Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug102 | ARCT-021 two lower dose priming Wiki | 1.00 |
drug2488 | Placebo booster Wiki | 1.00 |
drug2742 | Randomized booster Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2 doses (at two different dose levels), separated by 28 days or as 1 dose In adults 18 years of age and older
Description: Adverse events reported daily in a diary that reflect common symptoms or findings at the injection site following vaccination
Measure: Percentages of participants reporting solicited local adverse events Time: for 7 days following each dose administrationDescription: Adverse events reported daily in a diary that reflect generalized symptoms following vaccination
Measure: Percentages of participants reporting solicited systemic adverse events Time: for 7 days following each dose administrationDescription: spontaneously reported adverse events
Measure: Percentages of participants reporting adverse events Time: 28 days following each dose administrationDescription: unsolicited adverse events that meet the definition of serious
Measure: Percentages of participants reporting serious adverse events Time: Day 0 to Day 388Description: unsolicited adverse events that lead to healthcare provider visit
Measure: Percentages of participants reporting medically attended adverse events Time: Day 0 to Day 388Description: unsolicited adverse events associated with new diagnosis of chronic disease
Measure: Percentages of participants reporting new onset of chronic disease Time: Day 0 to Day 388Description: chemistry and hematology
Measure: Percentages of participants with abnormal chemistry and hematology values Time: Day 0 to Day 215Description: neutralizing antibody response
Measure: SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs Time: Day 0 to Day 388Description: neutralizing antibody response
Measure: Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs Time: Through Day 388Description: neutralizing antibody response
Measure: Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels Time: Through Day 388Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses
Measure: SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels, expressed as GMCs Time: Day 0 to Day 388Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses
Measure: Changes in SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs Time: Through Day 388Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses
Measure: Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels Time: Through Day 388Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports